Results 211 to 220 of about 2,176,373 (353)

Improving oral bioavailability of acalabrutinib using polymer-lipid hybrid nanoparticles: design, optimization, and <i>in vivo</i> pharmacokinetic evaluation. [PDF]

Nanoscale Adv
Sinha S, Ravi PR, Rashmi SR, Devaraju LK.   +3 more
europepmc   +1 more source

Population pharmacokinetics of TBAJ‐587 and its main metabolites—Evaluation of different loading dose strategies and early dose selection

British Journal of Clinical Pharmacology, EarlyView.
Background and Aim The rise of drug‐resistant tuberculosis (TB) poses a need for new drugs and combinations. TBAJ‐587, a new diarylquinoline (DARQ), has shown promising efficacy in preclinical studies. This work aimed to describe the pharmacokinetics (PK) of TBAJ‐587 and its metabolites M2 and M3 after single ascending dosing in healthy volunteers and ...
Albin A. M. Leding, Paul Bruinenberg, Almari Conradie, Jerry Nedelman, Antonio Lombardi, Dean Hickman, Ulrika S. H. Simonsson   +6 more
wiley   +1 more source

Absolute Oral Bioavailability and Bioequivalence of LSD Base and Tartrate in a Double-Blind, Placebo-Controlled, Crossover Study. [PDF]

Clin Pharmacol Ther
Arikci D, Holze F, Mueller L, Vizeli P, Rudin D, Luethi D, Hysek CM, Liechti ME.   +7 more
europepmc   +1 more source

Translation of a physiologically‐based pharmacokinetic model for dabigatran etexilate to the design of a safety and efficacy study in post‐partum women

British Journal of Clinical Pharmacology, EarlyView.
Aims To translate a PBPK model developed for the direct oral anticoagulant, dabigatran etexilate, the prodrug of dabigatran, based on data obtained from healthy men to healthy non‐pregnant, pregnant and post‐partum women. To evaluate safety and efficacy of dabigatran etexilate in post‐partum women using simulations and design a future clinical study to
Kayode Ogungbenro, Lorna Aucott, Farhad Kamali, Paul Ayuk   +3 more
wiley   +1 more source

Aprepitant-loaded solid lipid nanoparticles: a novel approach to enhance oral bioavailability. [PDF]

Beilstein J Nanotechnol
Hussain M, Farooq M, Saeed MA, Ijaz M, Adnan S, Masood Z, Waqas M, Ishaq W, Ameer N.   +8 more
europepmc   +1 more source

Nanocarriers for oral bioavailability enhancement

, 2009
Le but général de ce travail correspond à l'amélioration de la biodisponibilité de principes actifs connus pour leur faible biodisponibilité (testostérone) ou pour leur caractère lipidique (acides gras oméga 3). Des systèmes nanoparticulaires à base de lipides et des systèmes nanocristaux ont été développés notamment dans le cas de la testostérone ...
openaire   +1 more source

Effects of Renal and Hepatic Impairment on the Pharmacokinetics of Zilurgisertib

British Journal of Clinical Pharmacology, EarlyView.
Aim Small‐molecule activin receptor‐like kinase‐2 inhibitor zilurgisertib (INCB000928) is under investigation in a pivotal trial for the treatment of fibrodysplasia ossificans progressiva (FOP), an ultrarare genetic condition. This analysis assessed effects of renal and hepatic impairment on zilurgisertib pharmacokinetics.
Yan‐ou Yang, Yunlan Fang, Phillip Wang, Xiang Liu, Jay Getsy, Kevin Rockich   +5 more
wiley   +1 more source

Pharmacokinetics and oral bioavailability of ampicillin and its prodrug bacampicillin in chickens and turkeys. [PDF]

J Vet Sci
Guzelaydin K, Gunes Y, Anlas C, Yildirim M.   +3 more
europepmc   +1 more source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source

Anemoside B4 Rectal Thermosensitive In Situ Gel to Treat Ulcerative Colitis by Overcoming Oral Bioavailability Barriers with Absorption Enhancer-Assisted Delivery. [PDF]

Pharmaceutics
Lei X, Wang C, Xia M, Zhang G, Wang T, Chen Y, Huang Y, Wang T, Li D, Zhang W, Zhang G.   +10 more
europepmc   +1 more source